search
Back to results

Digital Implementation Support to Achieve Uptake and Integration of Task-Shared Care for Schizophrenia in Primary Care in India

Primary Purpose

Schizophrenia, Schizophrenia and Related Disorders, Psychosocial Functioning

Status
Not yet recruiting
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Community care for People with Schizophrenia in India (COPSI)
mindLAMP Mobile Application
Sponsored by
Harvard Medical School (HMS and HSDM)
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Schizophrenia focused on measuring schizophrenia, psychosocial intervention, digital technology, task sharing, implementation, smartphone app

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria: Primary diagnosis of schizophrenia per IDC-10 diagnostic criteria for research and an illness duration of greater than 12 months and overall moderate level of severity on the CGI-SCH scale At least one risk factor for early mortality (e.g. hypertension, diabetes, dyslipidemia, etc) Willingness to stay in the study area during the trial period Ability to operate a smartphone Exclusion Criteria: Major visual impairment or inability to operate a smartphone Cognitive impairment or diagnosis of dementia Planning to move out of the study area in the next 12 months Does not speak Hindi or Kannada

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    Active Comparator

    Arm Label

    COPSI plus mindLAMP

    COPSI

    Arm Description

    Participants allocated to this arm will be enrolled in COPSI and also have access to the mindLAMP mobile application. mindLAMP's materials will be available on demand for participants use.

    Participants allocated to this arm will be enrolled in COPSI alone. COPSI is delivered in three phases: 1) intensive engagement (0-3 months), including six to eight home visits by Community Health Officers; 2) stabilization phase (4-7 months) with sessions delivered once every 15 days; 3) and maintenance phase (8-12) with sessions delivered once a month.

    Outcomes

    Primary Outcome Measures

    Indian Disability Evaluation and Assessment Scale (IDEAS)
    - 4-domain self-report measure detecting the level of disability in psychiatric patients in India which generates a global score of severity of disability (0-20) with increasing scores indicating more severe disabilities

    Secondary Outcome Measures

    Positive and Negative Syndrome Scale (PANSS)
    30-item self-report measure of positive and negative symptoms and general psychopathology
    Generalized Anxiety Disorder Assessment-7 (GAD-7)
    7-item self-report measure of anxiety symptom severity based on DSM-5 criteria
    Patient Health Questionnaire-9 (PHQ-9)
    9-item self-report measure of depression severity based on DSM-5 criteria
    Clinical Global Impression-Schizophrenia (CGI-SCH) Scale
    7-item self-report measure of severity of schizophrenia, each component of the CGI-SCH is waited separately and does not yield a global score
    Brief Assessment of Cognition in Schizophrenia (BACS)
    Newly developed instrument to assess aspects of cognition in patients with schizophrenia

    Full Information

    First Posted
    September 12, 2023
    Last Updated
    September 12, 2023
    Sponsor
    Harvard Medical School (HMS and HSDM)
    Collaborators
    Beth Israel Deaconess Medical Center, Sangath, National Institute of Mental Health and Neuro Sciences, India, All India Institute of Medical Sciences, Bhopal
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT06043778
    Brief Title
    Digital Implementation Support to Achieve Uptake and Integration of Task-Shared Care for Schizophrenia in Primary Care in India
    Official Title
    Digital Implementation Support to Achieve Uptake and Integration of Task-Shared Care for Schizophrenia in Primary Care in India
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    September 2023
    Overall Recruitment Status
    Not yet recruiting
    Study Start Date
    January 2025 (Anticipated)
    Primary Completion Date
    July 2028 (Anticipated)
    Study Completion Date
    December 2028 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    Harvard Medical School (HMS and HSDM)
    Collaborators
    Beth Israel Deaconess Medical Center, Sangath, National Institute of Mental Health and Neuro Sciences, India, All India Institute of Medical Sciences, Bhopal

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    Yes

    5. Study Description

    Brief Summary
    Schizophrenia represents a significant contributor to the global burden of disease, with this burden disproportionately impacting low- and middle-income countries (LMICs). In India, the burden due to schizophrenia is further exacerbated by low access to effective psychosocial interventions aimed at promoting recovery, rehabilitation, and community tenure, as well as inadequate attention to managing co-occurring chronic medical conditions that result in significantly reduced life expectancy among those living with schizophrenia compared to the general population. A major driver of these alarming gaps in access to care for persons with schizophrenia in India is the limited capacity within primary care settings aimed at addressing the complex co-occurring mental health, physical health, and functional needs of this patient population. There now exists strong evidence demonstrating that community programs delivered in primary care and leveraging psychosocial interventions combined with linkage to specialty psychiatric services are effective for supporting treatment and recovery of schizophrenia in low-resource settings. We will leverage our existing collaboration and robust research infrastructure in both rural and urban settings in Madhya Pradesh and Karnataka, India to conduct a hybrid type 1 effectiveness-implementation trial to evaluate whether the use of a digital platform offers added clinical benefit and can support integration of this task shared care for schizophrenia into routine primary care settings. We will address the following aims: 1) evaluate whether the use of the mindLAMP digital platform can enhance the clinical effectiveness of task-shared community-based psychosocial rehabilitation (COPSI) for individuals with schizophrenia, and 2) determine whether the addition of mindLAMP to the delivery of the COPSI program has an impact on implementation metrics when compared to delivery of COPSI alone.
    Detailed Description
    Schizophrenia is one of the leading causes of disability due to mental disorders in low-income and middle-income countries (LMICs), such as India, with this burden disproportionately impacting lower income individuals who primarily access health care services through publicly run facilities. In 2017, it was estimated that there were over 3.5 million people in India living with schizophrenia, with an increasing prevalence of schizophrenia observed from 1990 to 2017 as the population ages and disease burden shifts to chronic conditions experienced in adulthood. Importantly, the burden of disability due to schizophrenia is often underestimated as many epidemiological studies do not adequately account for the added burden of chronic medical conditions, such as hypertension, heart disease, and diabetes that disproportionately impact individuals living with schizophrenia. Globally, the dramatically reduced life expectancy observed among individuals living with schizophrenia is largely due to preventable and treatable medical conditions. Recent epidemiological studies in India have further observed a mortality rate among individuals living with schizophrenia that is twice the rate observed in the general population, with calls for greater efforts to address this significant health disparity. In addition to recognizing the need to address the alarming care gap, where in India it is estimated that upwards of 75% of individuals living with schizophrenia do not have access to essential mental health care, urgent attention is also needed towards responding to the medical and physical health needs of this vulnerable patient population. Psychosocial interventions, focused on rehabilitation and skill-building, engaging in social activities, managing mental health symptoms, and promoting recovery and community reintegration, hold potential to reduce disability and improve mental health and functioning for individuals living with schizophrenia. Furthermore, building on recent compelling evidence from higher-income countries, community-based programs could be augmented with additional content aimed at addressing risk factors for early mortality, such as lifestyle behaviors, tobacco use, and management of co-occurring chronic medical conditions. Therefore, our study seeks to evaluate the use of a digital platform for supporting the clinical effectiveness and integration of task shared delivery of the evidence-based COPSI (Community care for People with Schizophrenia in India) program in primary care. We will build on important preliminary work led by project collaborators to support our aims to evaluate whether a novel digital platform can enhance the clinical effectiveness (Aim 1) and the integration (Aim 2) of an evidence-based psychosocial rehabilitation intervention for patients with schizophrenia in primary care settings in India.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Schizophrenia, Schizophrenia and Related Disorders, Psychosocial Functioning
    Keywords
    schizophrenia, psychosocial intervention, digital technology, task sharing, implementation, smartphone app

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Not Applicable
    Interventional Study Model
    Parallel Assignment
    Masking
    InvestigatorOutcomes Assessor
    Masking Description
    In this trial, the Outcome Assessors administering study assessments at baseline, midpoints and the endpoint will be masked to the intervention arm that participants are allocated to receive. The Study Investigators will also be masked to the intervention arm that participants are allocated to receive. Masking Outcome Assessors and Study Investigators will minimize potential bias due to knowledge of which arm the participant is allocated to, and can ensure unbiased ascertainment of study outcomes is possible. For allocation concealment, the intervention allocation for each participant will not be revealed to the participant until they have been enrolled into the trial, to avoid selection bias.
    Allocation
    Randomized
    Enrollment
    240 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    COPSI plus mindLAMP
    Arm Type
    Experimental
    Arm Description
    Participants allocated to this arm will be enrolled in COPSI and also have access to the mindLAMP mobile application. mindLAMP's materials will be available on demand for participants use.
    Arm Title
    COPSI
    Arm Type
    Active Comparator
    Arm Description
    Participants allocated to this arm will be enrolled in COPSI alone. COPSI is delivered in three phases: 1) intensive engagement (0-3 months), including six to eight home visits by Community Health Officers; 2) stabilization phase (4-7 months) with sessions delivered once every 15 days; 3) and maintenance phase (8-12) with sessions delivered once a month.
    Intervention Type
    Behavioral
    Intervention Name(s)
    Community care for People with Schizophrenia in India (COPSI)
    Other Intervention Name(s)
    Psychosocial rehabilitation intervention
    Intervention Description
    This intervention is designed to promote collaboration between the person with schizophrenia, their caregivers and the treatment team to deliver a flexible, individualized, and needs-based intervention. The COPSI intervention will be delivered by Community Health Officers in three phases: intensive engagement (0-3 months), stabilization phase (4-7 months), and maintenance phase (8-12).
    Intervention Type
    Behavioral
    Intervention Name(s)
    mindLAMP Mobile Application
    Intervention Description
    Participants in COPSI plus mindLAMP arm will have access to COPSI and the mindLAMP mobile application. mindLAMP has already been co-developed and culturally adapted by patients, family members, and clinicians at both Indian sites. Materials (articles, videos, web links, audio files, etc.) will be available on-demand and can be accessed by patients at any time. Community Health Officers will also schedule content to specific participants to promote engagement.
    Primary Outcome Measure Information:
    Title
    Indian Disability Evaluation and Assessment Scale (IDEAS)
    Description
    - 4-domain self-report measure detecting the level of disability in psychiatric patients in India which generates a global score of severity of disability (0-20) with increasing scores indicating more severe disabilities
    Time Frame
    Baseline, 6 months, and 12 months
    Secondary Outcome Measure Information:
    Title
    Positive and Negative Syndrome Scale (PANSS)
    Description
    30-item self-report measure of positive and negative symptoms and general psychopathology
    Time Frame
    Baseline, 6 months, and 12 months
    Title
    Generalized Anxiety Disorder Assessment-7 (GAD-7)
    Description
    7-item self-report measure of anxiety symptom severity based on DSM-5 criteria
    Time Frame
    Baseline, 6 months, and 12 months
    Title
    Patient Health Questionnaire-9 (PHQ-9)
    Description
    9-item self-report measure of depression severity based on DSM-5 criteria
    Time Frame
    Baseline, 6 months, and 12 months
    Title
    Clinical Global Impression-Schizophrenia (CGI-SCH) Scale
    Description
    7-item self-report measure of severity of schizophrenia, each component of the CGI-SCH is waited separately and does not yield a global score
    Time Frame
    Baseline, 6 months, and 12 months
    Title
    Brief Assessment of Cognition in Schizophrenia (BACS)
    Description
    Newly developed instrument to assess aspects of cognition in patients with schizophrenia
    Time Frame
    Baseline, 6 months, and 12 months
    Other Pre-specified Outcome Measures:
    Title
    Pittsburgh Sleep Questionnaire Index (PSQI)
    Description
    19-item self-report measure of sleep quality for patients with psychiatric disorders
    Time Frame
    Baseline, 6 months, and 12 months
    Title
    EuroQol-5D (EQ5D)
    Description
    25-item self-report standardized measure of health status and quality of life to provide a generic measure of health for clinical appraisal
    Time Frame
    Baseline, 6 months, and 12 months
    Title
    Social Functioning Scale (SFS)
    Description
    A measure with 7 subscales used to assess functioning in patients with psychosis
    Time Frame
    Baseline, 6 months, and 12 months
    Title
    Framingham Risk Score
    Description
    A measure used to assess cardiovascular risk using quantitative information to aid in targeting lower risk factors
    Time Frame
    Baseline, 6 months, and 12 months

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    Accepts Healthy Volunteers
    Eligibility Criteria
    Inclusion Criteria: Primary diagnosis of schizophrenia per IDC-10 diagnostic criteria for research and an illness duration of greater than 12 months and overall moderate level of severity on the CGI-SCH scale At least one risk factor for early mortality (e.g. hypertension, diabetes, dyslipidemia, etc) Willingness to stay in the study area during the trial period Ability to operate a smartphone Exclusion Criteria: Major visual impairment or inability to operate a smartphone Cognitive impairment or diagnosis of dementia Planning to move out of the study area in the next 12 months Does not speak Hindi or Kannada
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    John A Naslund, PhD
    Phone
    617-432-3712
    Email
    john_naslund@hms.harvard.edu
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    John A Naslund, PhD
    Organizational Affiliation
    Harvard Medical School (HMS and HSDM)
    Official's Role
    Principal Investigator
    First Name & Middle Initial & Last Name & Degree
    John Torous, MD
    Organizational Affiliation
    Beth Israel Deaconess Medical Center
    Official's Role
    Principal Investigator
    First Name & Middle Initial & Last Name & Degree
    Narayana Manjunatha, MD, MBBS
    Organizational Affiliation
    National Institute of Mental Health and Neuro Sciences, India
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Citations:
    PubMed Identifier
    36988785
    Citation
    Tyagi V, Khan A, Siddiqui S, Kakra Abhilashi M, Dhurve P, Tugnawat D, Bhan A, Naslund JA. Development of a Digital Program for Training Community Health Workers in the Detection and Referral of Schizophrenia in Rural India. Psychiatr Q. 2023 Jun;94(2):141-163. doi: 10.1007/s11126-023-10019-w. Epub 2023 Mar 29.
    Results Reference
    background
    PubMed Identifier
    36688236
    Citation
    Bondre AP, Shrivastava R, Raghuram H, Tugnawat D, Khan A, Gupta S, Kumar M, Mehta UM, Keshavan M, Lakhtakia T, Chand PK, Thirthalli J, Patel V, Torous J, Rozatkar AR, Naslund JA, Bhan A. A qualitative exploration of perceived needs and barriers of individuals with schizophrenia, caregivers and clinicians in using mental health applications in Madhya Pradesh, India. SSM Ment Health. 2022 Dec;2:100063. doi: 10.1016/j.ssmmh.2022.100063.
    Results Reference
    background
    PubMed Identifier
    36429654
    Citation
    Naslund JA, Tyagi V, Khan A, Siddiqui S, Kakra Abhilashi M, Dhurve P, Mehta UM, Rozatkar A, Bhatia U, Vartak A, Torous J, Tugnawat D, Bhan A. Schizophrenia Assessment, Referral and Awareness Training for Health Auxiliaries (SARATHA): Protocol for a Mixed-Methods Pilot Study in Rural India. Int J Environ Res Public Health. 2022 Nov 13;19(22):14936. doi: 10.3390/ijerph192214936.
    Results Reference
    background
    PubMed Identifier
    36386246
    Citation
    Lakhtakia T, Bondre A, Chand PK, Chaturvedi N, Choudhary S, Currey D, Dutt S, Khan A, Kumar M, Gupta S, Nagendra S, Reddy PV, Rozatkar A, Scheuer L, Sen Y, Shrivastava R, Singh R, Thirthalli J, Tugnawat DK, Bhan A, Naslund JA, Patel V, Keshavan M, Mehta UM, Torous J. Smartphone digital phenotyping, surveys, and cognitive assessments for global mental health: Initial data and clinical correlations from an international first episode psychosis study. Digit Health. 2022 Nov 8;8:20552076221133758. doi: 10.1177/20552076221133758. eCollection 2022 Jan-Dec.
    Results Reference
    background
    PubMed Identifier
    34512999
    Citation
    Rodriguez-Villa E, Rozatkar AR, Kumar M, Patel V, Bondre A, Naik SS, Dutt S, Mehta UM, Nagendra S, Tugnawat D, Shrivastava R, Raghuram H, Khan A, Naslund JA, Gupta S, Bhan A, Thirthall J, Chand PK, Lakhtakia T, Keshavan M, Torous J. Cross cultural and global uses of a digital mental health app: results of focus groups with clinicians, patients and family members in India and the United States. Glob Ment Health (Camb). 2021 Aug 24;8:e30. doi: 10.1017/gmh.2021.28. eCollection 2021.
    Results Reference
    background
    PubMed Identifier
    33541463
    Citation
    Rodriguez-Villa E, Mehta UM, Naslund J, Tugnawat D, Gupta S, Thirthalli J, Bhan A, Patel V, Chand PK, Rozatkar A, Keshavan M, Torous J. Smartphone Health Assessment for Relapse Prevention (SHARP): a digital solution toward global mental health - CORRIGENDUM. BJPsych Open. 2021 Feb 5;7(2):e48. doi: 10.1192/bjo.2021.6. No abstract available.
    Results Reference
    background
    PubMed Identifier
    36707524
    Citation
    Cohen A, Naslund JA, Chang S, Nagendra S, Bhan A, Rozatkar A, Thirthalli J, Bondre A, Tugnawat D, Reddy PV, Dutt S, Choudhary S, Chand PK, Patel V, Keshavan M, Joshi D, Mehta UM, Torous J. Relapse prediction in schizophrenia with smartphone digital phenotyping during COVID-19: a prospective, three-site, two-country, longitudinal study. Schizophrenia (Heidelb). 2023 Jan 27;9(1):6. doi: 10.1038/s41537-023-00332-5.
    Results Reference
    background

    Learn more about this trial

    Digital Implementation Support to Achieve Uptake and Integration of Task-Shared Care for Schizophrenia in Primary Care in India

    We'll reach out to this number within 24 hrs